QQQ   438.01 (-0.06%)
AAPL   175.11 (-0.82%)
MSFT   420.80 (-0.26%)
META   505.17 (-1.31%)
GOOGL   157.90 (+0.11%)
AMZN   186.28 (+0.08%)
TSLA   164.91 (-3.59%)
NVDA   883.80 (+0.22%)
AMD   162.02 (-0.77%)
NIO   3.96 (-3.65%)
BABA   71.35 (+0.08%)
T   16.40 (+0.55%)
F   12.44 (-1.35%)
MU   123.51 (+0.81%)
GE   154.92 (+0.19%)
CGC   7.44 (-4.62%)
DIS   114.57 (+0.49%)
AMC   2.58 (-2.64%)
PFE   26.08 (+0.85%)
PYPL   64.61 (+0.03%)
XOM   120.80 (+0.36%)
QQQ   438.01 (-0.06%)
AAPL   175.11 (-0.82%)
MSFT   420.80 (-0.26%)
META   505.17 (-1.31%)
GOOGL   157.90 (+0.11%)
AMZN   186.28 (+0.08%)
TSLA   164.91 (-3.59%)
NVDA   883.80 (+0.22%)
AMD   162.02 (-0.77%)
NIO   3.96 (-3.65%)
BABA   71.35 (+0.08%)
T   16.40 (+0.55%)
F   12.44 (-1.35%)
MU   123.51 (+0.81%)
GE   154.92 (+0.19%)
CGC   7.44 (-4.62%)
DIS   114.57 (+0.49%)
AMC   2.58 (-2.64%)
PFE   26.08 (+0.85%)
PYPL   64.61 (+0.03%)
XOM   120.80 (+0.36%)
QQQ   438.01 (-0.06%)
AAPL   175.11 (-0.82%)
MSFT   420.80 (-0.26%)
META   505.17 (-1.31%)
GOOGL   157.90 (+0.11%)
AMZN   186.28 (+0.08%)
TSLA   164.91 (-3.59%)
NVDA   883.80 (+0.22%)
AMD   162.02 (-0.77%)
NIO   3.96 (-3.65%)
BABA   71.35 (+0.08%)
T   16.40 (+0.55%)
F   12.44 (-1.35%)
MU   123.51 (+0.81%)
GE   154.92 (+0.19%)
CGC   7.44 (-4.62%)
DIS   114.57 (+0.49%)
AMC   2.58 (-2.64%)
PFE   26.08 (+0.85%)
PYPL   64.61 (+0.03%)
XOM   120.80 (+0.36%)
QQQ   438.01 (-0.06%)
AAPL   175.11 (-0.82%)
MSFT   420.80 (-0.26%)
META   505.17 (-1.31%)
GOOGL   157.90 (+0.11%)
AMZN   186.28 (+0.08%)
TSLA   164.91 (-3.59%)
NVDA   883.80 (+0.22%)
AMD   162.02 (-0.77%)
NIO   3.96 (-3.65%)
BABA   71.35 (+0.08%)
T   16.40 (+0.55%)
F   12.44 (-1.35%)
MU   123.51 (+0.81%)
GE   154.92 (+0.19%)
CGC   7.44 (-4.62%)
DIS   114.57 (+0.49%)
AMC   2.58 (-2.64%)
PFE   26.08 (+0.85%)
PYPL   64.61 (+0.03%)
XOM   120.80 (+0.36%)
CVE:IPA

ImmunoPrecise Antibodies (IPA) Stock Price, News & Analysis

C$6.50
+0.05 (+0.78%)
(As of 11/25/2022)
Today's Range
C$6.19
C$6.70
50-Day Range
C$6.50
C$6.50
52-Week Range
C$4.52
C$8.81
Volume
19,980 shs
Average Volume
19,376 shs
Market Capitalization
C$162.08 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A

About ImmunoPrecise Antibodies

ImmunoPrecise Antibodies Ltd., together with its subsidiaries, engages in antibody production and provision of related services in the United States, Canada, Europe, Australia, and internationally. The company offers a range of antibodies, enzymes, enzyme activity assays, arthritis animal products, proteins, deiminated proteins, organoid growth factors, and hybridoma products for research purposes. Its contract research organization services include custom antigen modeling, design, and manufacturing; B cell sorting, screening, and sequencing; custom, immune, and naive phage display production and screening; transgenic animals and multi-species antibody discovery; bi-specific, tri-specific, VHH, and VNAR (shark) antibody manufacturing; DNA cloning, protein and antibody downstream processing; antibody characterization on label-free biosensors and antibody engineering; transient and stable cell line generation; antibody optimization and humanization; hybridoma production with multiplexed, high-throughput screening, and clone-picking; and cryopreservation. The company has research collaboration agreements with Pierre Fabre S.A for antibody discovery; and Elektrofi, Inc. to explore a high-concentration formulation of COVID-19 antibody cocktail, PolyTope TATX-03. ImmunoPrecise Antibodies Ltd. was incorporated in 1983 and is based in Victoria, Canada.

IPA Stock Price History

IPA Stock News Headlines

2024 Oil Boom
Wall Street’s betting on new oil bull market… JP Morgan analysts have pegged the future price of oil at $380 per barrel. That would send oil companies skyrocketing.
ImmunoPrecise Antibodies Ltd. (TQB.F)
2024 Oil Boom
Wall Street’s betting on new oil bull market… JP Morgan analysts have pegged the future price of oil at $380 per barrel. That would send oil companies skyrocketing.
ImmunoPrecise Antibodies reports Q3 results
See More Headlines
Receive IPA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for ImmunoPrecise Antibodies and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Sector
Medical
Industry
Biotechnology
Sub-Industry
N/A
CIK
N/A
Fax
N/A
Employees
73
Year Founded
N/A

Profitability

Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
C$19.47 million
Cash Flow
C$0.77 per share
Book Value
C$2.67 per share

Miscellaneous

Free Float
N/A
Market Cap
C$162.08 million
Optionable
Not Optionable
Beta
N/A
10 "Recession Proof" Stocks That Will Thrive in Any Market Cover

Which stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.

Get This Free Report

Key Executives

  • Dr. Jennifer Lynne Bath Ph.D.
    CEO, Pres & Non-Independent Director
  • Mr. Brad McConn
    Chief Financial Officer
  • Dr. Ilse Roodink
    Chief Scientific Officer
  • Mr. David E. Orton
    Chief Operating Officer
  • Ms. Carla Dahl
    VP of Marketing
  • Dr. Barry Neil Duplantis
    VP of Client Relations

IPA Stock Analysis - Frequently Asked Questions

How have IPA shares performed in 2024?

ImmunoPrecise Antibodies' stock was trading at C$6.50 at the start of the year. Since then, IPA stock has increased by 0.0% and is now trading at C$6.50.
View the best growth stocks for 2024 here
.

What other stocks do shareholders of ImmunoPrecise Antibodies own?
How do I buy shares of ImmunoPrecise Antibodies?

Shares of IPA stock and other Canadian stocks can be purchased through an online brokerage account. Popular online brokerages with access to the Canadian stock market include BMO InvestorLine, CIBC Investor's Edge, Desjardins Online Brokerage, HSBC InvestDirect, Laurentian Bank Discount Brokerage, National Bank Direct Brokerage, Qtrade Investor, Questrade, RBC Direct Investing, Scotia iTrade, TD Direct Investing, and Virtual Brokers.
Compare Top Brokerages Here.

This page (CVE:IPA) was last updated on 4/15/2024 by MarketBeat.com Staff

From Our Partners